Systemic amyloidoses and proteomics: The state of the art

• Published in: EuPA open proteomics Vol. 11; no. C; pp. 4 - 10
• Main Authors: Lavatelli, Francesca, di Fonzo, Andrea, Palladini, Giovanni, Merlini, Giampaolo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-06-2016; Elsevier
• Subjects: Amyloidogenic proteins; Amyloidosis; Clinical proteomics; Proteotoxicity; Tissue biomarkers; Amyloidogenic proteins; Amyloidosis; Tissue biomarkers; Clinical proteomics; Proteotoxicity
• ISSN: 2212-9685; 2212-9685
• DOI: 10.1016/j.euprot.2016.02.003

[Display omitted]
•Proteomics is an established approach for diagnostic amyloid typing.•Mass spectrometry-based methods to analyze amyloid precursors have been developed.•Proteomic studies are ongoing to identify novel biomarkers and clarify disease mechanisms.
Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.